Fidelity mutual fund rides big pharma profits

Boasting a 12-month return of 27.3%--more than 10% better than both the Dow Jones Industrial Average and the S&P 500 returns--the Fidelity Select Pharmaceutical Portfolio recognizes "a lot of profit potential for the drug industry," despite patent expirations and generic competition. The fund comprises companies that research, manufacture, sell or distribute drugs. Its five-year return of 35.9% whupped the Dow's 9.7% and the S&P 500's 1.5%. The top five holdings: Pfizer, Valeant, Merck, Johnson & Johnson and Novo Nordisk. Story


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.